Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol

Background: The oral dual endothelin receptor antagonist bosentan improves exercise capacity and delays clinical worsening in patients with pulmonary arterial hypertension, but its use could delay starting intravenous epoprostenol, a life saving treatment. Methods: Survival in patients with function...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Sitbon, O, McLaughlin, V, Badesch, D, Barst, R, Black, C, Galie, N, Humbert, M, Rainisio, M, Rubin, L, Simonneau, G
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BMJ Group 2005
Gaiak:
Pulmonary Hypertension
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC1747276/
https://ncbi.nlm.nih.gov/pubmed/16055621
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/thx.2005.040618
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak